0001531209-18-000003.txt : 20181226
0001531209-18-000003.hdr.sgml : 20181226
20181226145152
ACCESSION NUMBER: 0001531209-18-000003
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20181226
DATE AS OF CHANGE: 20181226
EFFECTIVENESS DATE: 20181226
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Entrada Therapeutics, Inc.
CENTRAL INDEX KEY: 0001689375
IRS NUMBER: 813983399
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-328899
FILM NUMBER: 181252458
BUSINESS ADDRESS:
STREET 1: C/O FOLEY HOAG LLP
STREET 2: 155 SEAPORT BLVD.
CITY: BOSTON
STATE: MA
ZIP: 02210-2600
BUSINESS PHONE: 857-305-1825
MAIL ADDRESS:
STREET 1: C/O FOLEY HOAG LLP
STREET 2: 155 SEAPORT BLVD.
CITY: BOSTON
STATE: MA
ZIP: 02210-2600
FORMER COMPANY:
FORMER CONFORMED NAME: CycloPorters, Inc.
DATE OF NAME CHANGE: 20161104
D
1
primary_doc.xml
X0708
D
LIVE
0001689375
Entrada Therapeutics, Inc.
c/o Foley Hoag LLP
155 Seaport Blvd.
Boston
MA
MASSACHUSETTS
02210-2600
857-305-1825
DELAWARE
CycloPorters, Inc.
Corporation
true
2016
Louis
Tartaglia
c/o Foley Hoag LLP
155 Seaport Blvd.
Boston
MA
MASSACHUSETTS
02210-2600
Director
Kush
Parmar
c/o Foley Hoag LLP
155 Seaport Blvd.
Boston
MA
MASSACHUSETTS
02210-2600
Director
Dehua
Pei
c/o Foley Hoag LLP
155 Seaport Blvd.
Boston
MA
MASSACHUSETTS
02210-2600
Director
Anja
Harmeier
c/o Foley Hoag LLP
155 Seaport Blvd.
Boston
MA
MASSACHUSETTS
02210-2600
Director
Dipal
Doshi
c/o Foley Hoag LLP
155 Seaport Blvd.
Boston
MA
MASSACHUSETTS
02210-2600
Executive Officer
Director
Natarajan
Sethuraman
c/o Foley Hoag LLP
155 Seaport Blvd.
Boston
MA
MASSACHUSETTS
02210-2600
Executive Officer
Pharmaceuticals
Decline to Disclose
- 06b
false
2018-12-14
true
true
false
0
59021750
34021752
24999998
Total Offering Amount and Total Amount Sold include the conversion of outstanding indebtedness of the Issuer. A portion of the offering amount is reserved for additional closings.
false
10
0
0
645000
true
The above figure is an estimate of payments for services in the ordinary course expected to be made over the course of one year.
false
Entrada Therapeutics, Inc.
/s/ Dipal Doshi
Dipal Doshi
President & CEO
2018-12-22